top of page
Overview
Founded in 2017, Guangzhou Anjie Biomedical is a leading high-tech enterprise under the Respiratory Institute and Nanshan Research Institute, specializing in innovative tumor immunotherapies, therapeutic cancer vaccines, and stem cell applications.
We operate an international-standard GMP facility and is equipped with nucleic acid industrialization platform, viral production platform, stem cell preparation platform and immune cell preparation platform. With a fully integrated system spanning R&D, manufacturing, and clinical application, we deliver end-to-end solutions in CGT.
Our team has led major national and provincial scientific projects and collaborates with top global institutions to drive breakthroughs in cancer treatment and regenerative medicine.
Our Technology
Advanced Technologies
We operate a comprehensive suite of GMP-compliant platforms — including immune cell and stem cell manufacturing, viral production, nucleic acid industrialization, gene editing, and recombinant antigen development.
Leveraging advanced processes, stringent quality control, and fully integrated R&D-to-manufacturing capabilities, we deliver safe, high-quality, and innovative solutions that drive breakthroughs in cell and gene therapy worldwide.
bottom of page